Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: pgo-neil who wrote (78)	5/15/2007 11:16:01 AM
From: former_pgs	Respond to of 90

>I would think this unscheduled peek would have to be coordinated and approved by the FDA [the stat analysis as a minimum]. But I don't find any reference to that sort of coordination in the PR. How standard is this approach [with or without FDA approval]? < Strictly speaking, it only needs to be coordinated if they have an SPA and they want to maintain the integrity of the SPA. If not, they're free to take as many peeks as they wish; the obvious downside is that the more they do it in an unscheduled and undisciplined manner, the more chance they'll have to compromise the trial in the FDA's eyes.